Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Ddbio Co. Ltd. (Shang Hai) has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single matter is assigned to 1 distinct examiner, YOUNG, BRIAN ELLIS, who is also the busiest examiner with 1 busiest examiner pending office action. The prosecution is located within 1 distinct art unit. Because there is only a single active case, the entire portfolio's current activity is concentrated under the assigned examiner and the specified art unit.
This structure simplifies the prosecution landscape, as the company only needs to navigate the specific preferences and standards of YOUNG, BRIAN ELLIS within that single art unit. The 1 pending office action represents the full extent of the company's current engagement with the patent office in this technology area. Practitioners should note that the 1 distinct art unit involved will dictate the procedural rules and prior art types most relevant to the case. With only 1 distinct examiner to manage, the company can focus its resources on a singular prosecution style to resolve the 1 busiest examiner pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YOUNG, BRIAN ELLIS | 1 | 65.0% | +28.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18553413 | VECTOR AND METHOD FOR SCREENING FUNCTIONAL ANTIGEN-BINDING PROTEIN | YOUNG, BRIAN ELLIS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18553413 | VECTOR AND METHOD FOR SCREENING FUNCTIONAL ANTIGEN-BINDING PROTEIN | YOUNG, BRIAN ELLIS | — |
| Art Unit | Apps |
|---|---|
| 1684 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18553413 | VECTOR AND METHOD FOR SCREENING FUNCTIONAL ANTIGEN-BINDING PROTEIN | YOUNG, BRIAN ELLIS | 1684 | §103§112 | Non-Final OA | — | Pending | Sep 29, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDdbio Co. Ltd. (Shang Hai) has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Brian Ellis Young has the most, with 1 of Ddbio Co. Ltd. (Shang Hai)'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
